SweetSpot transforms completed clinical trial evidence into strategic intelligence for drug repurposing, indication prioritization, clinical development and study design — helping organizations make better investment and regulatory decisions.
High failure rates — especially in late-stage trials — persist because preclinical models poorly predict patient outcomes, and efficacy often fails despite early safety and pharmacology signals. The key challenge is identifying the right indication early.
We combine advanced analytics and deep therapeutic-area expertise to turn completed randomized clinical trial evidence into a clear, defensible roadmap — informing smarter, faster decisions across the drug development lifecycle.
Identify clinically meaningful therapeutic opportunities from completed randomized clinical trials, uncovering signals that traditional discovery methods miss.
Select indications, optimize endpoints and strengthen development programs before launching new studies, reducing avoidable trial risk.
Compare assets, evaluate competitive landscapes and prioritize investments with a shared, evidence-based frame of reference.
Support evidence-based decisions that maximize approval probability and commercial value across target indications.
The right indication. The right patients. The right benefit-risk balance — the specific indication and patient population where a drug delivers maximum benefit, acceptable risk and reaches the biology most likely to respond.
Strong, clinically meaningful efficacy — not marginal or statistically fragile effects.
A manageable safety profile appropriate to the population and setting.
The biology most likely to respond, defined by indication, patient characteristics and dose/regimen context.
Randomized controlled trials are patient physiological perturbation experiments. By systematically re-examining dose, target engagement and outcomes, we reveal heterogeneity of response, integrate benefit-risk evidence, and define the sweet spot for each asset.
Randomized controlled trials (drug vs. control), drug mode of action, disease landscape and patient-level outcomes are aggregated and harmonized.
Drug effect on trial outcomes, Bayesian probability-of-success modeling, and effect prediction in new indications.
Drug mode of action and clinical effect are linked to disease and trial outcomes across the full evidence base.
Proof of pharmacology, benefit-risk assessment, and predicted effect in new indications — a clinical development roadmap.
Our platform integrates the full landscape of relevant clinical trial data to guide indication selection with greater confidence and speed.
We evaluate your assets and objectives to strategically guide your program's roadmap, delivering a targeted indication strategy supported by rigorous evidence, robust analytics and a trusted network of therapeutic-area experts.
100% Life Sciences. Our entire commitment to life-science innovation is built to improve program development and deliver faster, positive outcomes for patients.
In-Depth Expertise. By fully understanding your program, we determine your asset's potential and define the most relevant roadmap forward.
Rigorous, Data-Driven Analytics. Our indication-finding pipeline turns dense clinical evidence into clear, decision-ready intelligence — with retrospective validation that's easy to verify on drugs already on the market.
SweetSpot was born from a simple observation, made across hundreds of clinical trials: the evidence needed to find a drug's next indication is usually already sitting in completed trial data, waiting to be re-read the right way. We combined deep clinical trial biostatistics expertise with drug pharmacology and modern AI-driven analytics to build a platform that turns that evidence into a repeatable, defensible discipline.
A PhD statistician with experience as study statistician and line manager across more than 100 clinical trials spanning Phase I to Phase IV, in therapeutic areas including respiratory, pediatrics, ophthalmology, nephrology and cardiovascular disease. Francois founded SweetSpot to bring together rigorous clinical trial biostatistics, drug pharmacology (PK/PD modeling, Bayesian methods) and AI-driven analytics — building the evidence-based indication-finding discipline the industry has been missing.
SweetSpot is a global drug development technology company.
Headquarters
30 rue Bon Air
Genappe, Belgium
No authorization required from the manufacturer, and no reliance on proprietary or contracted datasets.
The average cost of drug development exceeds $800M — with significant de-risking available simply by targeting the right indication. SweetSpot aligns its model with your outcome.
"Complexity is rarely solved by doing more. It's solved by doing better."